Hypothesis: the same drug is protective in the islet and harmful in the parathyroid and the growth plate
also called tissue-divergent menin inhibition · islet benefit parathyroid harm
We think blocking menin helps insulin-making cells while harming the parathyroid glands and the growing skeleton, because those tissues use menin for different jobs on different timescales. If that is right, the same child can benefit and be harmed at the same time, in different organs.
The same thing, for a scientist
The synthesis this beat needs, stated so it can be killed. Claim: menin inhibition produces **tissue-divergent** outcomes because the menin-dependent restraint being released differs by tissue in both its target and its recovery kinetics. In the beta cell, released restraint drives compensatory proliferation that is physiologically bounded and reverses when the stimulus ends, giving net benefit over months [E1][E2]. In the parathyroid chief cell, the released restraint is on **secretion** as well as growth, so PTH rises within weeks and there is no physiological counter-regulation to bound it [E3][E4]. In the skeleton, the released restraint lands on a developmental window that does not reopen, so even a short exposure can be permanent [E5]. The prediction is not that the drug is safe or unsafe but that **its sign depends on the tissue and on whether that tissue has a bounded recovery**.
Discriminating predictions
P1. In revumenib-treated patients, fasting glucose falls or is unchanged while intact PTH rises, in the same individuals. The two should be uncorrelated or inversely correlated, not co-directional. Testable today on existing trial chemistry data.
P2. Intact PTH rises with drug exposure (AUC or trough) after adjustment for creatinine and phosphate; glucose does not track creatinine. Testable today on existing PK and laboratory data.
P3. After the last dose, PTH returns towards baseline within weeks (secretory disinhibition, reversible), whereas any height-velocity deficit does not recover (developmental window, irreversible). Requires the off-treatment arm that exp-endocrine-surveillance-panel-menin-treated-children proposes and that FDA's PMR does not compel.
P4. In an animal given a clinical menin inhibitor for 12 weeks and then withdrawn, islet proliferation normalises while parathyroid chief-cell hyperplasia and growth-plate closure do not.
P5. A menin inhibitor applied to primary human parathyroid cells abolishes TGF-beta suppression of PTH secretion at concentrations at or below those that displace KMT2A - i.e. the endocrine effect is not a high-dose artefact.
What would kill it
See data.falsifiers. The cleanest single kill is P1 failing in the co-directional sense: if glucose rises on treatment in the same patients whose PTH rises, then the beta-cell benefit does not translate at clinical exposures and the whole divergence framing collapses into a simpler one-sided toxicity story - which is a legitimate and useful outcome, and one this beat should be equally willing to reach.
Prior and why it is not higher
Set at 0.35. It is not higher because (a) no clinical menin inhibitor has ever been tested on an islet, a parathyroid cell or a chondrocyte, so the entire tissue-divergence argument is assembled from tool-compound and genetic data; (b) the human biochemical pattern on revumenib - phosphate up, creatinine up - resembles renal secondary hyperparathyroidism more than primary parathyroid autonomy, which is a direct strike against the parathyroid arm [see mechanism-parathyroid-autonomous-menin-loss-causes-hypercalcaemia]; and (c) the growth-plate arm has no mechanism at all, only a toxicology finding and an absence of literature.
| statement | Menin inhibition is net protective in the pancreatic islet and net harmful in the parathyroid and the growing skeleton, because the restraint released differs by tissue in target and in recovery kinetics. |
|---|---|
| origin | literature-gap |
| prior probability | 0.35 |
predictions
[ "Fasting glucose falls or is unchanged while intact PTH rises in the same revumenib-treated patients", "PTH rise tracks drug exposure after adjustment for creatinine and phosphate; glucose does not track creatinine", "PTH returns towards baseline within weeks of the last dose; height-velocity deficit does not recover", "In an animal withdrawal study, islet proliferation normalises while parathyroid hyperplasia and growth-plate closure do not", "A clinical menin inhibitor abolishes TGF-beta suppression of PTH secretion in primary human parathyroid cells at or below KMT2A-displacing concentrations" ]
experiments
[ "exp-clinical-menin-inhibitor-on-primary-parathyroid-cells", "exp-glucose-and-islet-function-in-menin-inhibitor-treated-children", "exp-endocrine-surveillance-panel-menin-treated-children" ]
analyses
[ "ana-paediatric-subgroup-and-covariate-reanalysis-menin-inhibitor-labs" ]
falsifiers
[ "Fasting glucose RISES on treatment in the same patients whose PTH rises - the tissue-divergence framing collapses into one-sided toxicity", "The PTH rise is fully explained by creatinine and phosphate in a covariate model, with no residual exposure dependence - the parathyroid arm is not on-target", "A clinical menin inhibitor produces no change in TGF-beta-suppressed PTH secretion in primary human parathyroid cells at achievable concentrations", "Islet proliferation under a clinical menin inhibitor fails to appear at human exposures - the benefit arm does not translate and only the harms remain", "Growth-plate closure in the juvenile rat is shown to be secondary to the mineral axis rather than a direct skeletal effect, making it a consequence of the parathyroid arm rather than an independent tissue" ]
- If the hypothesis is right, a benefit in one organ cannot be traded against harm in another, because the child gets both and only one of them is reversible.
- A tissue-divergent drug cannot be dose-optimised for safety: the concentration that spares the parathyroid also spares the leukaemia.
- The hypothesis's own benefit arm depends entirely on tool compounds; if it fails to translate, the graph is left with the harms and no offset.
- Is there a tissue in which menin inhibition is neutral, and what distinguishes it?
- Could intermittent dosing preserve the leukaemic effect while allowing endocrine tissues to recover between cycles?
- Does the divergence hold in a child, whose islet, parathyroid and growth plate are all in different developmental states from an adult's?
- E1moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Pharmacological menin inhibition for 8-12 weeks improves glucose handling and raises beta-cell mass in mice.
Menin-regulated Pbk controls high fat diet-induced compensatory beta cell proliferation. · Ma J, Xing B, Cao Y, He X, et al. · EMBO Molecular Medicine 2021What this evidence cannot show
Tool compound, n=4-5, adult mice, no tumour assessment.
Evidence that argues against this (1)
- Longer or complete Men1 loss in the same tissue gives insulinoma and beta-cell identity loss. Li F et al. 2015
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Menin down-regulation in the beta cell is a bounded physiological event that ends with its stimulus.
Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. · Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, et al. · Science 2007What this evidence cannot show
Mouse pregnancy; boundedness is inferred from the physiology, not measured under drug.
Evidence that argues against this (1)
- A drug is not bounded by a physiological stimulus, so the analogy holds only for as long as the prescription is short. Syndax Pharmaceuticals et al. 2026
- E3moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Menin is required for TGF-beta to restrain PTH secretion, so parathyroid disinhibition does not require growth and can appear within weeks.
Menin inactivation leads to loss of transforming growth factor beta inhibition of parathyroid cell proliferation and parathyroid hormone secretion. · Sowa H, Kaji H, Kitazawa R, Kitazawa S, Tsukamoto T, Yano S, et al. · Cancer Research 2004What this evidence cannot show
Human parathyroid cells from secondary hyperparathyroidism; antisense knockdown, not pocket inhibition.
Evidence that argues against this (1)
- The ziftomenib label reports no parathyroid abnormality at all, so a class-wide parathyroid pharmacology is not corroborated. Kura Oncology et al. 2025
- E4established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database
Intact PTH rose in 34% of revumenib-treated patients over a median 2.5-month exposure.
REVUFORJ (revumenib) tablets, for oral use - US Prescribing Information (SPL version 5, published 20 Feb 2026) · Syndax Pharmaceuticals, Inc. · DailyMed / FDA Structured Product Label, setid 6eb3cdbc-0e74-477d-82d6-3bb172d3f63f 2026What this evidence cannot show
Pooled adults and children; confounded by creatinine rising in 38% and phosphate in 51%.
Evidence that argues against this (1)
- That confounding is severe and the renal explanation is the null this hypothesis has to beat. Syndax Pharmaceuticals et al. 2026
- E5established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database
Revumenib caused irreversible femoral growth-plate closure in juvenile rats at ~2x human AUC.
REVUFORJ (revumenib) tablets, for oral use - US Prescribing Information (SPL version 5, published 20 Feb 2026) · Syndax Pharmaceuticals, Inc. · DailyMed / FDA Structured Product Label, setid 6eb3cdbc-0e74-477d-82d6-3bb172d3f63f 2026What this evidence cannot show
Label summary; no mechanism, no zone-level histology, no human data.
Evidence that argues against this (1)
- No growth-plate finding appears on the ziftomenib label, so the skeletal arm may be compound-specific rather than on-target. Kura Oncology et al. 2025
P5: does a clinical menin inhibitor abolish TGF-beta suppression of PTH secretion at or below KMT2A-displacing concentrations?
P3: PTH recovers off drug, height velocity does not; the off-treatment arm this hypothesis needs is the one that experiment already specifies and FDA's PMR does not compel
- supports →Hypothesis: the PTH rise on menin inhibitors is on-target and exposure-dependent, not renal
Generalises the parathyroid-only hypothesis to a tissue-divergent one, and shares its central discriminator: does the PTH rise track drug exposure after adjustment for creatinine and phosphate
The islet-benefit arm rests entirely on this one in-vivo tool-compound experiment
- depends on →The label says monitor bone growth in children. Not one paper has asked what menin does in a growth plate
The skeletal arm has a toxicology finding and no mechanism; this is the weakest leg of the hypothesis and is flagged as such
P1 and P3: does fasting glucose fall while PTH rises in the same patients, and does either persist after the last dose?
P2: does the PTH rise track drug exposure after adjustment for creatinine and phosphate? Answerable today on existing data
thymic epithelium is a tissue in which menin-inhibitor effect has never been examined